These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33121216)

  • 1. Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany.
    Wachter R; Klebs S; Balas B; Kap E; Engelhard J; Schlienger R; Bruce Wirta S; Fonseca AF
    ESC Heart Fail; 2020 Oct; 7(5):2318-2330. PubMed ID: 33121216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.
    Wachter R; Fonseca AF; Balas B; Kap E; Engelhard J; Schlienger R; Klebs S; Wirta SB; Kostev K
    Eur J Heart Fail; 2019 May; 21(5):588-597. PubMed ID: 30972918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
    Wachter R; Viriato D; Klebs S; Grunow SS; Schindler M; Engelhard J; Proenca CC; Calado F; Schlienger R; Dworak M; Balas B; Bruce Wirta S
    Postgrad Med; 2018 Apr; 130(3):308-316. PubMed ID: 29446691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption: A STROBE-compliant study.
    Chen W; Liu Y; Tang L; Li Z; Liu Y; Dang H
    Medicine (Baltimore); 2021 Jul; 100(30):e26809. PubMed ID: 34397739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of sacubitril/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study.
    Zeymer U; Groves R; Hupfer S
    Herz; 2024 Oct; 49(5):385-392. PubMed ID: 38656397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia.
    Badreldin HA; Korayem GB; Alenazy BA; Aljohani MH; Alshaya OA; Al Sulaiman K; Alabdelmuhsin L; Alenazi H; Almutairi DM; Alanazi F; Alobathani SK; Alqannam GM; Almadani O; Aljuhani O; Hafiz A; Aljowaie G; Basha E; Alqahtani T; Alhussein M
    Medicine (Baltimore); 2023 Dec; 102(51):e36699. PubMed ID: 38134075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    Nordberg Backelin C; Fu M; Ljungman C
    ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.
    Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Solomon SD; Starling RC; Velazquez EJ; Williamson K; Zieroth S; Braunwald E
    J Card Fail; 2023 Jun; 29(6):922-930. PubMed ID: 36796671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
    Visco V; Radano I; Campanile A; Ravera A; Silverio A; Masarone D; Pacileo G; Correale M; Mazzeo P; Dattilo G; Giallauria F; Cuomo A; Mercurio V; Tocchetti CG; Di Pietro P; Carrizzo A; Citro R; Galasso G; Vecchione C; Ciccarelli M
    ESC Heart Fail; 2022 Oct; 9(5):2909-2917. PubMed ID: 35702942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (THESEUS).
    Dieterle T; Schaefer S; Meyer I; Ackermann G; Ahmed K; Hullin R
    ESC Heart Fail; 2020 Aug; 7(4):1626-1634. PubMed ID: 32369265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
    Myhre PL; Liu Y; Kulac IJ; Claggett BL; Prescott MF; Felker GM; Butler J; Piña IL; Rouleau JL; Zile MR; McMurray JJV; Ward JH; Solomon SD; Januzzi JL
    Eur J Heart Fail; 2023 Aug; 25(8):1396-1405. PubMed ID: 37401523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure.
    Feng Z; Wang X; Zhang L; Apaer R; Xu L; Ma J; Li X; Che H; Tang B; Xiong Y; Xia Y; Xiao J; Su X; Wang Y; Dou X; Chen J; Mei L; Xue Z; Kong Y; Li S; Zhang H; Lin T; Wen F; Fu X; Tao Y; Fu L; Li Z; Huang R; Ye Z; He C; Shi W; Liang X; Ke G; Liu S
    Blood Purif; 2022; 51(3):270-279. PubMed ID: 34753147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
    Myakala K; Jones BA; Wang XX; Levi M
    Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
    Zuo C; Li X; Fan L; Li J; Tian D; Chen C; Li X; Lv Q
    J Clin Pharm Ther; 2022 Oct; 47(10):1539-1547. PubMed ID: 35649528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study.
    Riaz M; Smith SM; Dietrich EA; Pepine CJ; Park H
    Pharmacotherapy; 2021 Sep; 41(9):710-721. PubMed ID: 34170559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.
    Pascual-Figal D; Wachter R; Senni M; Belohlavek J; Noè A; Carr D; Butylin D
    ESC Heart Fail; 2018 Apr; 5(2):327-336. PubMed ID: 29239515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.